A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated d6-Dextromethorphan Hydrobromide d6-DM/Quinidine Sulfate Q) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A study for the treatment of agitation in patients with Alzheimer's Disease using study drug AVP-786
Sponsor: Avanir
Enrolling: Male and Female Patients
IRB Number: 7180
U.S. Govt. ID: NCT02442765
Contact: Devangere Devanand: 646-774-8658 / dpd3@columbia.edu
Additional Study Information: The objectives of the study are to evaluate the effectiveness, safety, and tolerability of study drug AVP-786 compared to placebo (contains no active medication), for the treatment of agitation in patients with dementia of the Alzheimers type. Eligible patients will be randomly assigned at the Baseline visit to receive AVP-786 or matching placebo. Study medication will be administered orally twice daily from Day 1 through Day 85. Patients (or caregivers) will self-administer study medication on all study days except on the clinic-visit days when patients will be administered their morning dose of study medication at the clinic in the presence of site personnel, regardless of the time of day. Patients will have at least a 50% chance of receiving AVP-786 at some point during the study.
This study is closed
Davangere Devanand, MD
Do You Qualify?
Have you been diagnosed with Alzheimer's Disease (AD)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Devangere Devanand